BriaCell Appoints Jamieson Bondarenko to its Board of Directors

BERKELEY, Calif., and VANCOUVER, British Columbia, February 12, 2019 – BriaCell Therapeutics Corp. (TSX-V:BCT) (OTCQB:BCTXF) (“BriaCell” or the “Company”), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, today announces the appointment of Jamieson Bondarenko to the Company’s Board of Directors. Jamieson Bondarenko, CFA, CMT, is an active investor and provides strategic capital …

BriaCell Announces Switch to Novel Frozen Formulation for Lead Cancer Drug Candidate, Upcoming Attendance at Biotech Showcase™ 2019 and Presentation at Keystone Symposia Conference

· Completed development of a novel frozen formulation of Bria-IMT™ for on-demand shipment to clinical sites to accommodate higher patient volumes at reduced per-dose costs. · Upcoming attendance at Biotech Showcase in San Francisco, Jan. 7-9, 2019. · Abstract accepted by Keystone Symposia for presentation of advances in Bria-IMT™ and BriaDX™ programs, Jan. 20-24, 2019. …

BriaCell Presents Positive Efficacy Data with Lead Cancer Drug Candidate in Phase IIa Monotherapy and Excellent Initial Safety Data in Combination with KEYTRUDA® at a Major Breast Cancer Conference

· Interim data indicate an excellent safety profile for the combination regimen in advanced breast cancer patients. Initial efficacy data is expected in first quarter of 2019; · Confirmed positive proof-of-concept with Bria-IMT™ Monotherapy demonstrates promising anti-tumor activity with excellent safety and tolerability in advanced breast cancer patients. BERKELEY, Calif., and VANCOUVER, British Columbia, December …

UPDATED – BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium

Note: This Press Release contains amendments to the press release previously issued on Nov. 19, 2018 · Positive proof of concept data with Bria-IMT™ Monotherapy will highlight potent anti-tumor activity and an excellent safety profile for Bria-IMT™ in advanced breast cancer. · Patient dosing is ongoing in a combination study of Bria-IMT™ with KEYTRUDA® (by …

BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium

· Positive proof of concept data with Bria-IMT™ Monotherapy will highlight potent anti-tumor activity and an excellent safety profile for Bria-IMT™ in advanced breast cancer. · Patient dosing is ongoing in a combination study of Bria-IMT™ with KEYTRUDA® (by Merck & Co., Inc.) in advanced breast cancer. · Interim safety data of the combination study …

BriaCell Therapeutics Corp.’s CEO Talks Personalized Breast Cancer Treatment Technology with Uptick Newswire’s Stock Day Podcast

Phoenix, Nov. 6, 2018 (GLOBE NEWSWIRE) – BriaCell Therapeutics Corp. (“BriaCell,” the “Company”) (TSX-V: BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that Dr. Bill Williams, BriaCell’s president and CEO, was recently interviewed by Everett Jolly of Stock Day. “BriaCell is developing the first off-the-shelf, personalized …

BriaCell Initiates Dosing in Phase I/IIa Combination Study with KEYTRUDA® or YERVOY®

· Patient dosing is underway in a combination study of Bria-IMT™ with KEYTRUDA® (by Merck & Co., Inc.) or YERVOY® (by Bristol-Myers Squibb Company) in advanced breast cancer. · KEYTRUDA® and YERVOY® have been highly recognized for their potent immune boosting properties – Nobel Prize in Medicine 2018 – validating BriaCell’s strategy to use these …

BriaCell Announces Positive Phase IIa Proof of Concept Data in Advanced Breast Cancer; Initiates Combination Study

· BriaCell has achieved positive proof of concept in the Phase IIa study of Bria-IMT™ in advanced breast cancer patients · Data shows promising anti-tumor activity of Bria-IMT™ in heavily pre-treated advanced breast cancer patients · Impressive Phase IIa efficacy data is similar or superior to those of other approved breast cancer drugs of similar …

BriaCell Therapeutics Corp. Discusses its Plan to Revolutionize Cancer Immunotherapy in Exclusive NetworkNewsWire Audio Interview

NEW YORK (Sept 25, 2018) – via NetworkWire – NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview with BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) (“BriaCell” or “the Company”), focused on developing a targeted and safe …

Coverage Initiated for BriaCell Therapeutics Corp. via NetworkNewsWire

NEW YORK, Sept. 21, 2018 (GLOBE NEWSWIRE) — via NetworkWire – BriaCell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V) (BriaCell or the Company), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announces that it has selected NetworkNewsWire (“NNW”) to assist the Company with its corporate communications initiatives. BriaCell is currently developing a targeted …